WVE Stock Price, Chart, Stats & News
Wave Life Sciences Ltd. (WVE) does not currently pay a dividend.
WVE chart
Fundamentals
Gross margin | 84.50% |
Operating margin | -504.09% |
Pretax margin | -478.33% |
Net margin | -478.33% |
Effective tax rate | – |
ROA | -32.01% |
ROE | -84.99% |
D/E | 0.03x |
Interest coverage ratio | – |
WVE valuation
P/E | – |
P/S | 28.04x |
P/B | 2.18x |
P/CF | -6.17x |
P/FCF | -6.42x |
P/OCF | -6.17x |
PEG | 0.09x |
EV multiple | -8.88x |
About
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD).
Similar securities
Based on sector and market capitalization
